Key Takeaways
- A year of two halves: FY22 net profit collapsed to Rs. 170 crores from Rs. 442 crores, dragged by a Rs. 232 crore COVID inventory write-off and Rs. 46 crore credit loss provision, while the underlying export business strengthened on the back of the Revlimid launch.
- Revlimid is the new anchor: The Lenalidomide launch contributed meaningfully in Q4, with ~70% of stock to be sold in FY23, promising a lumpy but transformative earnings stream that management expects to be recurring and stable.
- The base business is a treadmill: The domestic oncology portfolio is stable but not growing, and the export generic business loses 10–20% of value annually, requiring constant new launches just to hold ground.
- Bold bets define the strategy: Management is channeling Revlimid cash into higher-risk R&D and litigation-driven opportunities like CTPR, explicitly framing the model as chasing jackpots where uncertainty is high but payoffs are large.
- What to watch next quarter: The pace of Revlimid stock liquidation in Q1 FY23, the July court hearing on CTPR that could unlock a near-term agrochemical opportunity, and any acquisition to expand the domestic footprint.
Revlimid: The Earnings Reset
- Launch status: Lenalidomide launched in the US in Q4 FY22, with only one month of sales recognized in the quarter; the majority of stock remains unsold and will flow through FY23.
- Volume phasing: A good portion of Revlimid stock will be recognized in Q1 FY23, tapering off in Q2 and Q3, with earnings bumping up again in Q4 when a new allocation is received.
- Recurring confidence: Management is very confident Revlimid will be recurring and stable revenue; when second-wave generics enter, Natco expects a higher share and higher quantity.
- Remaining strengths: Launch of the remaining two strengths is expected after Reddy's launch, since Reddy's holds First-to-File on those.
- Multi-year tail: Management expects meaningful money over the next 3–4 years depending on staggered competitor entry, though it calls any speculation on price erosion premature.
- Pricing opacity: Management declined to comment on price erosion versus the open market, stating partner Teva does not want to reveal the pricing strategy, and also declined to share the profit share amount accrued.
- Profit share confirmed: Despite declining to discuss the amount, management confirmed the profit share percentage as "one third... 30%" when pressed by a different analyst.
Rajeev Nannapaneni: "I think everybody is coming in a staggered way and I think there should be a meaningful amount of money that we are going to make over the next 3-4 years depending on how people enter... the erosion and all it is hard to speculate, I think it will be very premature to talk about how market will form over the new few years."
The COVID Hangover: Write-Offs and Clean-Up
- Inventory write-off: Natco took a conservative call to write off Rs. 232 crores of COVID-related and nonmoving inventory to remove the hangover and provide clarity for investors; not all stock is zero-value and some can be written back.
- Credit loss provision: An additional Rs. 46 crores was provided towards estimated credit losses, also related to COVID products.
- Net outcome: Management characterized the COVID bet as a disaster that, on a net basis, did not really make any money after accounting for profits made in prior years against the write-offs.
- Domestic reversal: The higher domestic decline in Q4 was partly due to taking a fair reversal on some COVID products.
- Inventory policy shift: Post-COVID, Natco now keeps 8–12 months of inventory for key products to service demand comfortably and manage supply chain challenges; margins made are much higher as a result.
Rajeev Nannapaneni: "I think if you look at the money that we have made over the last few years and look at the write-off, more or less I think on a net basis, it has not really made any money, I think it has been a disaster, but it is what it is, I think business bet that we have made and that has not work."
Base Business: The Treadmill
- Export generics reality: Everything Natco makes in the export generic business reduces every year by 10, 15, 20%; what was made in 2017, 2018 would see a 50% collapse today, requiring constant new launches to replace lost revenue.
- Subsidiary replacement: Subsidiaries now represent almost 80 to 100% revenue for quarter, replacing Rs. 400 crores of lost base business sales, but not at the same profitability level because expenses have risen.
- Domestic oncology: Growth has stalled because of a high base and price erosion in the portfolio; the company is not spread out in multiple segments.
- Domestic base stability: Excluding reversals, the base domestic business is about Rs. 400 crores, stable but not growing or degrowing; half of any 10–15% growth comes from new launches.
- OPEX market share: Market share on OPEX is stable at 40-50%, though the overall market has moved to orals like Dimethyl Fumarate.
- Afinitor: Doing very well, driving export growth in the base business; has a generic in the US and a sole generic in Brazil, with reasonable US market share and expecting approval in Canada.
- Apixaban: Doing extremely well, with a run rate of about Rs. 2.5- Rs. 3 crores of quarter on the secondary; one of the bigger achievements.
- Base profit run-rate: Quarterly profit in the Rs. 50 to Rs. 60 hard range, with the base business having grown sequentially even after adjusting for the Q3 Rs. 100 crore profit share.
Rajeev Nannapaneni: "We need to understand how generics business works, I think if you look at the export generic business, everything that we will do will keep reducing every year by 10, 15, 20%... essentially it is a tread mill, so you need to keep coming and launching new products and replacing what you are losing on your base business."
Pipeline and Litigation Bets
- CTPR opportunity: Management is very excited about the CTPR opportunity, subject to how the court case goes; the compound patent expires in August 2022, an additional process patent litigation was filed two months before launch, and the next court hearing is in July.
- CTPR competitive landscape: If Natco clears the way, management believes it will be in the first wave; limited competition is expected due to litigation, creating an exclusive or semi-exclusive situation.
- Three FTF filings: Filed this year: Semaglutide, Acalabrutinib (both have multiple pilots), and Idealisib (likely the only FTF).
- Agrochemical pipeline: Very interesting products to be filed in the next 12 months; CTPR is the biggest near-term point; the focus will be on India with a B2C approach going directly to consumers.
- Glatiramer lawsuit: Management called the Copaxone lawsuit frivolous and premature to speculate on, noting Natco has been in the market for more than 5–6 years; declined to comment on the plaintiff's objectives or whether the outcome rests with the marketing partner.
- Upcoming launch: Another big launch is coming in FY23, to be announced shortly.
Rajeev Nannapaneni: "We look for jackpot opportunities and go after that and there will be uncertainty always, I will not, I never will shy away from saying that, but this is what we do, but when we deliver, we deliver big."
Subsidiaries and Geographic Expansion
- Canada: Revlimid launched 4–5 months ago through Natco's own front end; doing extremely well with 40–50% market share; one of the most profitable subsidiaries.
- Brazil: Turned profitable during the year.
- US frontend acquisition: Natco acquired a US frontend to plug in and launch its own products; all Para IV pipeline products Natco makes will flow through this front end.
- Dash frontend: Completed acquisition; currently losing Rs. 4–6 crores per quarter operationally; management hopes to reach breakeven in 1–1.5 years with launches from the India pipeline, targeting revenue growth from Rs. 1.7–1.8 crore to Rs. 3–3.5 crore, then holding stable while waiting for Para IV jackpots over the next 6–7 years.
- Australia: Received approval for both Pomalidomide and Lenalidomide; working with partner Juno for launch.
- Strategic objective: Build a broad-based multi-country generic business with core markets in Brazil, Canada, India, and the US.
Capital Allocation and R&D
- R&D ramp: Expenses have increased because the cashflow buffer from Revlimid is being invested in more interesting and bold R&D ideas; management was not prepared to quantify the normalized run-rate when asked.
- R&D categories for FY23: Three buckets: bio-clinical/clinical studies, litigation expenses, and raw material/exhibit batch write-offs.
- Other expenses doubled YoY: From Rs. 100 crores to Rs. 200 crores, driven by approximately Rs. 40 crores in ECL provisions and Rs. 50–60 crores in additional R&D spending funded by surplus cash.
- Inorganic appetite: Management stated that larger disruptive moves will require inorganic acquisition because the generic business is extremely competitive and not growing organically; near-term cash flows from Revlimid are being used for R&D, while acquisitions remain on the radar for domestic expansion.
- CAPEX not required: Enough capacity exists for domestic and regulated markets, with two plants for the US.
- Pipeline sustainability: The goal is to build a pipeline that can sustain over the next 7 to 10 years.
Rajeev Nannapaneni: "The thing you need to understand overall generic business and I think if you look at most generic businesses are not growing. It is extremely competitive and the only way you can do something disruptive as you need to buy, otherwise you are not going to get growth and this is the elephant in a room..."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revlimid stock liquidation | ~70% of current Revlimid stock sold, with a good portion in Q1, tapering in Q2/Q3, and bumping up in Q4 with new allocation | FY23 |
| Revlimid recurring revenue | Management very confident Revlimid will be recurring and stable; higher share and quantity expected when second-wave generics enter | Multi-year, undated |
| Revlimid remaining strengths | Launch of remaining two strengths after Reddy's entry | Undated, contingent on Reddy's launch |
| Domestic growth target | 10–12% growth in the base business | Next year (FY23) |
| Dash frontend breakeven | Breakeven expected with launches from India pipeline | 1–1.5 years |
| CTPR clarity | Clarity on agro inventory and path forward expected; patent expires August 2022, next court hearing July 2022 | Next 2 months |
| Upcoming launch | Another big launch in FY23, to be announced shortly | FY23 |
| Agrochemical pipeline | Very interesting products to be filed | Next 12 months |
Key Metrics
| Metric | Q4 FY22 |
|---|---|
| Consolidated revenue | ₹610.6 cr, against ₹359.7 cr in Q4 last year |
| Consolidated net loss | ₹50.5 cr, against a loss of ₹53 cr in Q4 last year |
| FY22 consolidated revenue | ₹2,043.8 cr, against ₹2,155.7 cr last year |
| FY22 consolidated net profit | ₹170 cr, against ₹442 cr last year |
| Inventory write-off (COVID products) | ₹232 cr for FY22 |
| Provision for estimated credit loss | ₹46 cr for FY22 |
| Normalized domestic base business (ex-COVID) | ~₹400 cr |
| Base business quarterly PAT (ex-Revlimid, incl. subs and India) | ₹50–60 cr |
| Revlimid profit share | one third / 30% |
| Revlimid stock sold in Q4 | ~20–30%; ~70% of stock expected to be sold in FY23 |
| Revlimid Canada market share | 40–50% (per sales team, IMS not yet out) |
| Afinitor share of base business sales | ~30% |
| Apixaban (generic Eliquis) secondary run rate | ₹2.5–3 cr per quarter |
| Agro inventory and supplier commitments at risk | ₹85 cr |
| Dash US frontend loss in March quarter | ₹4–6 cr |